China Tracker - Details for American Oriental Bioengineering (AOBI)

 American Oriental Bioengineering
Shares Outstanding (MRQ): 78.18 mill
New Shares / Dilution (TTM): -11.28 mill-12.61%
New Shares / Dilution (since Dec 31, 2008): -4.08 mill-4.96% 
Cash (MRQ): 111.43 mill128.41%
Account Receivables (MRQ): 46.87 mill54.01%
Account Receivables (Q/Q): -33.73 mill-41.85%
Long-Term Debt (MRQ): 136.87 mill157.73%
Revenue Growth (Q/Q): -37.62% 
Revenue Growth (Y/Y): -3.25%
Net Income Growth (Q/Q): -66.55% 
Net Income Growth (Y/Y): -70.41%
EPS Growth (Y/Y): -66.14%
Net Margin (Q/Q): 1.8% (3.3%)-1.50% 
Net Margin (Y/Y): 1.8% (5.8%)-4.00% 
EPS | P/E (2 MRQ Projection): $0.0911.77 
CFPS | P/CF (2 MRQ Projection): $0.571.95
Price/Sales (2 MRQ Projection): 0.32
Price/Book (MRQ): 0.20
Auditor: Weinberg & Company 
 Forward Projections (Fiscal Year)
EPS | P/E (Estimates updated 2010-10-31): $0.353.17
 Basic Facts and History (show more)
Reporting Type: U.S. Company (10-K Filings) 
Going Public: Reverse Merger on 2001-12-18 
Uplisting to Senior Exchange: on 2005-07-18 at $1.72 (-35.47% since Uplisting)

 Business Outlook

Recent Chain of Events:
2012-06-15 -- Last SEC Filing
2012-06-15 -- Auditor Change
2012-05-29 -- Delisting from NYSE Amex
2012-03-16 -- Trading halted by NYSE Amex
2011-11-14 -- Last Quarterly/Annual Report: Q3/FY2011 ended September 30, 2011

(Source: Trading China, 2012-09-30)

Our first quarter results reflect our continuing efforts on profitability focus and cost control. We dynamically adjusted our product mix to minimize the negative impact from the increased costs of certain raw materials and the government's price reduction on certain drugs. In addition, we believe our continued investments in CAPEX and R&D will give us a competitive advantage in for the long term, especially under the stricter regulatory environment.

(Source: PR Newswire, 2011-05-09)

Our growth in 2010 was consistent with our expectations and reflects our continued efforts on profitability focus and cost control. We dynamically adjust our product mix to minimize the negative impact from the increased cost of certain raw materials, as well as the government's price cut on certain drugs. In addition, our long-term investments in science and technology have achieved initial results, which were demonstrated by the strong sales from the new products supported by our R&D efforts. Overall, we remain enthusiastic about the tremendous opportunities in China's healthcare sector, and we are looking forward to more progress in the fiscal year ahead.

(Source: PR Newswire, 2011-03-14)

    see all Business Outlook notes

 Analyst Coverage (show more)
2011-03-15Brean MurrayDowngradeHoldn/a
2010-11-15Brean MurrayReiterationBuy$3.70

AOBI is currently followed by 4 analysts. All 4 give the stock a neutral rating.

    see all Analyst Ratings

 Recent Financings
2009-10-09Filing$150.00 mill--

 Investor Presentations
2009-10-01 (PDF)   DOWNLOAD (right click, save as)
Healthcare & Drugs
READ: Score Cards Explained
DETAILS: Safety/Risk Model for AOBI
Current Price:  $1.11
F10k Day (2002-02-22): 48.00%$0.75
2009 Close: -76.13%$4.65
2010 Close: -53.75%$2.40
2011 Close: -50.45%$2.24
High (2012-03-14): -30.19%$1.59
Low (2012-07-13): 2,120.00%$0.05
Exchange: PNK
Market Capitalization: 86.78 mill
Total Shares: 78.18 mill
Float: n/a
Avg Volume: n/a
Last Quarter: 2011-03-31
Revenue (MRQ): 52.00 mill
Net Income (MRQ): 0.92 mill
Op. Cash Flow (MRQ): 21.60 mill
all financial data provided without warranty